Science & Enterprise subscription

Follow us on Twitter

  • Statista prepared a chart this week with data from an annual report by the Intellectual Property Owners Association… https://t.co/PjH8cSi7Kc
    about 21 mins ago
  • New post on Science and Enterprise: Infographic – IBM Leads Again in Patent Awards https://t.co/m34QBDnUNB #Science #Business
    about 22 mins ago
  • An engineering team designed sensors that stick on the skin and form a network with radio-frequency signals to trac… https://t.co/OcMWP7cnKn
    about 19 hours ago
  • New post on Science and Enterprise: Skin Sensor Network Tracks Health Functions https://t.co/lvTmYRJGnv #Science #Business
    about 19 hours ago
  • A new project examines brain pathologies leading to development of Alzheimer's disease in Americans of Hispanic des… https://t.co/im8f9Pi0yn
    about 24 hours ago

Please share Science & Enterprise

Diagnostics Developer Secures $100M Series C Financing

Currency dice (MD4 Group/Flickr)Biocartis, a diagnostic systems company in Lausanne, Switzerland says it completed raising €71 million (US$100 million) in series C equity funds, led by the company’s senior management and  backed by current and new investors, as well as industrial collaborators. Series C financing is the third round of equity funding after start-up.

Biocartis develops compact molecular and genomic diagnostic systems, considered key to the adoption of personalized medicine. The company expects to launch its first system — code named Apollo — in 2013, which it says has been modeled after consumer electronics designed for everyday use by a broad range of customers in a wide range of settings.

The company says Apollo will be able to deliver results as accurate as those generated in a specialized clinical lab in as little as one hour from sample preparation to read out. It is expected to detect and quantify multiple DNA- or RNA-based biomarkers in a variety of patient sample types. The technology has also been designed for integration with health care IT systems.

The Apollo system, says Biocartis, has been developed in collaboration with Philips Corporate Technologies. Other collaborators include diagnostics company bioMerieux and Janssen Pharmaceuticals, a division of Johnson & Johnson.

Leading the investment round are Biocartis senior management including Rudi Pauwels, the company’s founder and CEO, as well as Peter Verhaeghe, managing partner of the Brussels law firm VVGB. Investors include Philips, Johnson & Johnson Development Corporation, and the Wellcome Trust, among others.

Read more:

Photo: MD4 Group/Flickr

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.